Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Powell

Showing results (461-470 of 493) with videos related to

Pageof 50
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung CancerHossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.
The Lancet. Oncology|October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyCorey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
Neurobiology of Aging|April 17, 2013
Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeatAshley R Jones, Ione Woollacott, Aleksey Shatunov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 StudyMarina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.
Plos One|June 2, 2016
Influence of Coding Variability in APP-Aβ Metabolism Genes in Sporadic Alzheimer's DiseaseCeleste Sassi, Perry G Ridge, Michael A Nalls, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2020
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB StudySteven F Powell, Kathryn A Gold, Mark M Gitau, et al.
Journal of Alzheimer'S Disease : JAD|June 7, 2017
No Genetic Overlap Between Circulating Iron Levels and Alzheimer's DiseaseMichelle K Lupton, Beben Benyamin, Petroula Proitsi, et al.
Nature Communications|October 17, 2019
Genome-wide association mapping of date palm fruit traitsKhaled M Hazzouri, Muriel Gros-Balthazard, Jonathan M Flowers, et al.
JCO Precision Oncology|February 9, 2022
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational StudySteven F Powell, Elie G Dib, Jonathan S Bleeker, et al.
Pageof 50

Showing results (461-470 of 493) with videos related to

Sort By:
Pageof 50
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung CancerHossein Borghaei, Corey J Langer, Shirish Gadgeel, et al.
The Lancet. Oncology|October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyCorey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.
Neurobiology of Aging|April 17, 2013
Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeatAshley R Jones, Ione Woollacott, Aleksey Shatunov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 StudyMarina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.
Plos One|June 2, 2016
Influence of Coding Variability in APP-Aβ Metabolism Genes in Sporadic Alzheimer's DiseaseCeleste Sassi, Perry G Ridge, Michael A Nalls, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2020
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB StudySteven F Powell, Kathryn A Gold, Mark M Gitau, et al.
Journal of Alzheimer'S Disease : JAD|June 7, 2017
No Genetic Overlap Between Circulating Iron Levels and Alzheimer's DiseaseMichelle K Lupton, Beben Benyamin, Petroula Proitsi, et al.
Nature Communications|October 17, 2019
Genome-wide association mapping of date palm fruit traitsKhaled M Hazzouri, Muriel Gros-Balthazard, Jonathan M Flowers, et al.
JCO Precision Oncology|February 9, 2022
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational StudySteven F Powell, Elie G Dib, Jonathan S Bleeker, et al.
Pageof 50